Fluoroquinolones have been linked to the rise of drug-resistant organisms, Clostridioides difficile infections and ruptures of Achilles tendons. The FDA has issued several warnings about their side effects.
Researchers from Ann Arbor-based Michigan Medicine reviewed prescriptions from 48 Michigan hospitals.
They found discharge-related prescriptions accounted for two-thirds of the fluoroquinolone supply prescribed to the nearly 12,000 patients treated for pneumonia or urinary tract infections.
The hospitals that said they are trying to cut fluoroquinolone use were twice as likely to discharge patients with a new prescription for a drug in that group, the researchers found.
Overall, one-third of the patients included in the study got a fluoroquinolone prescription at the end of their hospital stay, despite guidelines calling for restricted use.
“Fluoroquinolone antibiotics are easy to use but carry a lot of risk for patients and society at large,” said lead study author Valerie Vaughn, MD. “These results show we need to focus on not just their use in hospitals, but also in the prescriptions that we send patients home with. Discharge-prescribing is a big loophole.”
More articles on clinical leadership & infection control:
Formulary restriction, preauthorization can help reduce restricted antibiotic use
Former Mount Carmel physician linked to patient deaths overrode pharmacists’ safety warning, report says
Why combining nurse perspective with scientific approach improves care
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.